Abstract:BACKGROUND:Prostate specific membrane antigen (PSMA) can facilitate the growth, migration, and invasion of the LNCaP prostate cancer cell lines, but the underlying molecular mechanisms have not yet been clearly defined. Here, we investigated whether PSMA serves as a novel regulator of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling by employing PSMA knockdown model and PI3K pharmacological inhibitor (LY294002) in LNCaP prostate cancer cells.METHODS:PSMA knockdown had been stably established by transfecting with lentivirus-mediated siRNA in our previous study. Then, LNCaP cells were divided into interference, non-interference, and blank groups. We first testified the efficacy of PSMA knockdown in our LNCaP cell line. Then, we compared the expression of PSMA and total/activated Akt by Western blotting in the above three groups with or without LY294002 treatment. Furthermore, immunocytochemistry was performed to confirm the changes of activated Akt (p-Akt, Ser473) in groups. Besides, cell proliferation, migration, and cell cycle were measured by CCK-8 assay, Transwell analysis, and Flow cytometry respectively.RESULTS:After PSMA knockdown, the level of p-Akt (Ser473) but not of total-Akt (Akt1/2) was significantly decreased when compared with the non-interference and blank groups. However, LY294002 administration significantly reduced the expression of p-Akt (Ser473) in all the three groups. The results of immunocytochemistry further confirmed that PSMA knockdown or LY294002 treatment was associated with p-Akt (Ser473) down-regulation. Decrease of cell proliferation, migration, and survival were also observed upon PSMA knockdown and LY294002 treatment.CONCLUSIONS:Taken together, our results reveal that PI3K/Akt signaling pathway inhibition may serve as a novel molecular mechanism in LNCaP prostate cancer cells of PSMA knockdown and suggest that Akt (Ser473) may play a critical role as a downstream signaling target effector of PSMA in this cellular model.

PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis

PTEN regulate angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells

Pi3k-Akt Signaling Is Involved In The Regulation Of P21(Waf/Cip) Expression And Androgen-Independent Growth In Prostate Cancer Cells

Phosphatidylinositol 3-Kinase Signaling Controls Levels of Hypoxia-Inducible Factor 1.

Targeting PI3K/Akt signaling in prostate cancer therapy

PTEN Regulates Angiogenesis and VEGF Expression Through Phosphatase-Dependent and -Independent Mechanisms in HepG2 Cells

PTEN and GSK3 Β : Key Regulators of Progression to Androgen-Independent Prostate Cancer

Essential Role of AKT-1/Protein Kinase Bα in PTEN-Controlled Tumorigenesis

Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3-kinase/Akt pathway during anti-angiogenesis therapy

The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models

Silencing of PIK3C2B inhibits the proliferation and invasion of human prostate cancer PC-3 cells

Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells

Important Roles of PI3K/AKT Signaling Pathway and Relevant Inhibitors in Prostate Cancer Progression

Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer

[P2Y Purinergic Receptor Activated PI-3K/Akt Signaling Pathway in Regulation of Growth and Invasion of Prostatic Cancer].

PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate

PI3K/Akt signal transduction pathway and tumor

PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications

Ang1/Tie2 Induces Cell Proliferation and Migration in Human Papillary Thyroid Carcinoma Via the PI3K/AKT Pathway

PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer

Prostate Specific Membrane Antigen Knockdown Impairs the Tumorigenicity of LNCaP Prostate Cancer Cells by Inhibiting the Phosphatidylinositol 3-Kinase/akt Signaling Pathway.